Neuroprotection is unlikely to be effective in humans using current trial designs: An opposing view

Stroke

Volumn 33, Issue 1, 2002, Pages 308-309

  Lees, Kennedy R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Clinical trials; Neuroprotection; Stroke assessment

Indexed keywords

NEUROPROTECTIVE AGENT;

BRAIN PERFUSION; BRAIN PROTECTION; DRUG EFFICACY; DRUG TOLERANCE; HUMAN; NEUROPROTECTION; PRIORITY JOURNAL; SHORT SURVEY; STROKE;

EID: 0036142768     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/str.33.1.308     Document Type: Short Survey

References (9)

1. Neuroprotection
2. Prospects for improved neuroprotection trials in stroke
3. Recommendations for standards regarding preclinical neuroprotective and restorative drug development
4. Comparison of neuroprotective data for NXY-059 in animal models with the STAIR criteria
5. Lubeluzole in acute ischemic stroke treatment: Lack of efficacy in a large phase III study with an 8-hour window
6. Inference on multiple endpoints in clinical trials with adaptive interim analyses
7. Glycine antagonist gavestinel in neuroprotection (GAIN International) in patients with acute stroke: A randomised controlled trial
8. Glycine antagonist in neuroprotection for patients with acute stroke
9. Value of minimisation for treatment allocation in acute stroke trials